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Abstract
Understanding the basis of the binding of a T cell receptor (TR) to the peptide-MHC (pMHC) complex is essential due to the
vital role it plays in adaptive immune response. We describe the use of computed binding (free) energy (BE), TR paratope,
pMHC epitope, molecular surface electrostatic potential (MSEP) and calculated TR docking angle (h) to analyse 61 TR/pMHC
crystallographic structures to comprehend TR/pMHC interaction. In doing so, we have successfully demonstrated a novel/
rational approach for h calculation, obtained a linear correlation between BE and h without any ‘‘codon’’ or amino acid
preference, provided an explanation for TR ability to scan many pMHC ligands yet specifically bind one, proposed a
mechanism for pMHC recognition by TR leading to T cell activation and illustrated the importance of the peptide in
determining TR specificity, challenging the ‘‘germline bias’’ theory.
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Introduction
For maximal immunological protection against a multitude of
pathogens, the adaptive immune response in higher jawed
vertebrates causes major histocompatibility complexes (MHC) or
human leukocyte antigens (HLA) in human, to bind antigenic
peptides (p) and present them as peptide-MHC (pMHC)
complexes on the surface of antigen-presenting cells (APC), for
recognition by T cell receptors (TR) [1]. This TR/pMHC
interaction is relatively feeble compared to other important
interactions between the molecules of the immune system [2],
yet strong enough to trigger TR mediated activation of T cells,
thereby eliciting an immediate immune response to either destroy
infected cells directly (via CD8+ associated cytotoxic T cells) or
activate (via CD4+ associated helper T cells) other immune system
cells like B cells and macrophages to carry out the immune
response. More than ten years after the first TR/pMHC structure
was reported [3], the interaction between TR and pMHC
complexes is still an enigma [4], due in part to the complexities
of the molecules involved in this association. The two constant
domains (Ca and Cb) of the TR are linked to variable domains
(Va and Vb encoded by rearranged variable (V), diversity (D) and
joining (J) genes, V-J and V-D-J genes, respectively), whose CDR1,
CDR2 and CDR3 loops recognize pMHC [5]. The MHC
proteins are composed of two chains, a and b, with the a chain (I-
ALPHA) alone forming the peptide-binding groove in MHC class
I (MHC-I) proteins, while MHC class II (MHC-II) proteins have
both chains a (II-APLHA) and b (II-BETA) forming the peptide
binding site [6].
The mechanism responsible for the specificity of the TR/pMHC
interactionsremains anunsolvedproblem.The TR"germlinebias",
in which TR/pMHC binding is independent of the nature of the
peptide and MHC restriction or TR specificity is based on specific
conserved contacts between TR V (variable) domains and MHC
proteins that co-evolve [7], has been proposed as one of the
solutions. It however, is not as simple as it sounds. This is due to the
mechanisms of combinatorial diversity and N-diversity of the
variable domains of TR that create 1012 TR per individual [5], the
very high number of MHC alleles and most of all a large number of
antigenic peptides. The cross-reactivity of MHC proteins means
that the TR briefly scans through several pMHC complexes before
actually interacting with a specific one. While this brief scanning by
the TR may provide an explanation for the feeble TR/pMHC
interactions alluded to earlier, it becomes increasingly important to
understand the minute aspects of this vital binding over a broad
spectrum of data. Garcia and co-workers [4] have provided highly
influential hypotheses using a dataset of 20 TR/pMHC structures,
implying that the contacts between CDR1 and CDR2 loops of TR
variable domains and MHC helices are germline-encoded leading
to the conclusion that TR/pMHC binding is peptide independent.
Also inferred in their study is that whatever the TR docking angle,
the bound complexes have equivalent binding free energies (DG;
referred to here as binding energy (BE) in kcal/mol) at ‘‘codon’’ or
amino acid positions A, B and C (as depicted inset of Figure 2b in
[4]). Therefore, the main questions we address in this work are: (1)
whether there are specific energetically equivalent binding energy
‘‘codon’’ or amino acid positions associated with TR binding angles
as suggested by Garcia et al., [4] and; (2) if the ‘‘germline bias’’
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these questions, we have also arrived at a possible answer to another
lingering question in immunology, viz. how can a TR scan through
many pMHC complexes and yet specifically bind to one?
We have analyzed the currently available non-redundant dataset
of 61 TR/pMHC X-ray crystal structures from MPID-T2 database
(http://biolinfo.org/mpid-t2) [8], which were originally obtained
from the Protein Data Bank (PDB) [9] and verified with IMGT/
3Dstructure-DB (http://www.imgt.org/3Dstructure-DB/), the refer-
ence database for immunoglobulins, T cell receptors and MHC
structures [10,11], to determine three major factors that greatly
contribute to or influence TR/pMHC binding: (1) binding energy
(BE) between TR and pMHC complexes [12-14]; (2) molecular
surface electrostatic potential (MSEP) at TR and pMHC interfaces
[15,16] and; (3) angle formed by the major axis of TR and the linear
axisof thecognate peptide whenTR is bound topMHC(TR docking
angle in degrees; herein referred to as ‘h’ when calculated and as
‘diagonal’ when obtained from literature) [4,17]. Using in vitro
immuno-assays, researchers have previously reported that weak BE
between TR and pMHC complexes ascribe weak agonistic (T cell
activating) properties to the pMHC complexes and vice versa [18–20].
Thisinference is basedon the underlying ideathatthe strengthof TR
binding to pMHC plays a vital role in stabilizing the half-life of the
TR/pMHC complex, consequently resulting in T cell signalling or
activation. Thissignificant finding laid the foundation for us to use BE
as a useful parameter in discriminating weak-, moderate- and strong
pMHC agonists. MSEP has been used in structure based drug design
and in understanding protein-protein interactions by crystallogra-
phers for many years [21]. It has also been applied as a successful
molecular descriptor for large assemblies of molecules such as
microtubules and ribosome [22]. Not only does it include all major
aspects of protein-protein interaction, it is also distinctive of molecular
shapes. Therefore, we have employed MSEP as an analytical tool to
dissect TR/pMHC interactions.
Using computed MSEP of pMHC and TR interacting
interfaces we are able to successfully explain the common docking
geometry of almost all TR proteins on their respective pMHC
binding interfaces. We then discuss a linear correlation between
calculated BE and h, which provides an answer to our first
question. A TR paratope (residues on TR interface that contact
the pMHC) and pMHC epitope (residues on pMHC interface that
contact the TR) analysis, with a focus on conserved residues
among pMHC and TR interacting sequence patterns, was
conducted in hope of finding certain broadly conserved structural
determinants that would constitute the ‘‘smoking gun’’ of ‘‘MHC
bias’’ [4]. Finally, we also discuss a new and valuable grouping
(clustering) system for TR proteins based on their binding site
similarities (from TR paratope analysis), pMHC recognition
similarities (from pMHC epitope analysis) and similarities in
MSEP displayed by their respective interacting pMHC interfaces
(see Methods section for details). The results of MSEP similarity
calculation at the pMHC interface along with our TR paratope
and pMHC epitope analyses also suggest a weakening of
‘‘germline bias’’ theory over a larger dataset and highlight the
significant role played by the peptide in determining TR
specificity, thereby, providing an explanation to our second query.
Our detailed results are as follows.
Results
BE as a determinant of weak-, moderate- and strong
pMHC agonists
It has been reported earlier that lack of enough number of TR/
pMHC structures makes differentiation of weak- and moderate-
agonists from strong-agonists or true-agonists from antagonists,
almost impossible without immunological assays [15]. However,
the availability of a relatively large dataset (61 TR/pMHC
structures) together with our comprehensive BE analysis has now
made it possible to discriminate strong- from weak- and moderate-
agonists for both TR/pMHC-I and TR/pMHC-II structures.
Figure 1 shows a plot of the calculated BE between the TR and
pMHC-I structures (Figure 1a) and pMHC-II structures
(Figure 1b). As seen, this graphical representation gives a clear
understanding of the discriminatory power of this analysis. We
have computed an overall mean of -15.5 kcal/mol and
215.4 kcal/mol and standard deviation of 63.3 kcal/mol and
62.7 kcal/mol for TR/pMHC-I and TR/pMHC-II structures,
respectively. With cutoffs defined by mean and standard deviation
values, we have discriminated weak-, moderate- and strong
pMHC agonists. Since BE is also referred to as binding free
energy, the highest negative value is considered the best. Among
TR/pMHC-I complexes, weak TR agonists have a BE between 0
and 212.2 kcal/mol (=215.5+3.3), moderate-agonists (shaded
area in Figure 1a) have BE values between 212.2 and
218.8 kcal/mol (=215.5–3.3) while strong-agonists gave BE
values below 218.8 kcal/mol and are potential T cell activators.
TR/pMHC-II structures with a BE between 0 and 212.7 kcal/
mol (=215.4+2.7) are classified as weak-agonists, complexes with
BE between 212.7 and 218.1 kcal/mol (=215.4–2.7) are
moderate-agonists (shaded area in Figure 1b) and strong-agonists
have a BE value below 218.1 kcal/mol and could be more
efficient in activating the T cells.
Figure 1a shows a few TR/pMHC-I complexes (PDB codes
1lp9, 2uwe, 2j8u, 2jcc, 3kpr and 3kps in Table S1) having BE
values well below 220 kcal/mol, reaching up to 223 kcal/mol.
These pMHC ligands are thus very strong-agonists with greater
propensity to elucidate T cell activity, concordant with the results
obtained from experimental immuno-assays by Miller et al. [23],
for the pMHC ligands in the PDB structures 2uwe and 2jcc and
Macdonald et al. [24], for the pMHC ligands in the PDB structures
3kpr and 3kps, respectively. Overall, it was observed that there
were 10 (20%) weak-, 34 (68%) moderate- and 6 (12%) strong-
binding agonists amongst the TR/pMHC-I complexes. The list of
34 moderate agonists includes pMHC ligands from the PDB
structures 2ak4, 2bnr and 2nx5 (Table S1) which have been
previously confirmed by cytotoxicity assays [25–27]. Among the
10 weak-agonists is the pMHC from the PDB structure 2ol3,
whose lower propensity to elucidate T cell activity was validated
by the low level of cytotoxicity observed from cytotoxicity assays
by Mazza et al. [28]. Similarly, Figure 1b highlights the presence of
one such strong-agonist (PDB code 3mbe in Table S1) amongst
TR/pMHC-II structures with a BE of 222 kcal/mol. Observa-
tions made by Yoshida et al. [29], from functional immuno-assays
clearly indicate the strong-agonistic and T cell stimulating
properties of the pMHC complex in the PDB structure 3mbe.
Amidst the 11 TR/pMHC-II complexes, our analysis established
1( ,9%) weak-, 9 (,82%) moderate- and 1 (,9%) strong-binding
agonist. These results suggest why a very small percentage (9–12%
from our results) of peptide antigens that are predicted to be T cell
epitopes by computational methodologies can actually elicit T cell
response in vitro [30].
pMHC interfaces display a ring of charged amino acids
for recognition by complementarily charged TR Va and
Vb domain interfaces
Most TR proteins that recognize pMHC complexes bind on the
central regions of G-ALPHA1 and G-ALPHA2 helices (Figure 2a)
for pMHC-I and G-ALPHA and G-BETA helices (Figure 2e) for
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pMHC-I (PDB code 2e7l; Figure 2a) and pMHC-II (PDB code
1u3h; Figure 2e) clearly depict a sequential clockwise ring of
positively and negatively charged residues on G-ALPHA1 and G-
ALPHA2 helices (MHC-I), G-ALPHA and G-BETA helices
(MHC-II) which interact with complementarily charged residues
on CDR1 and CDR2 loops of TR a and b variable domains
(Figure 2b, f). This was the case in almost all pMHC and TR
interacting regions that were analyzed. Interestingly, previous
characterization studies on TR/pMHC complexes have revealed
molecular interactions along similar regions on the TR and
pMHC interfaces [31,32], thereby, supporting our MSEP driven
Figure 1. Standard curves for the frequency of computed BE between the TR and pMHC complexes for a. TR/pMHC-I complexes and
b. TR/pMHC-II complexes. On the X-axis is the range of BE and on the Y-axis is the number of structures having their BE within these ranges. The
pink lines signify the mean BE values. Standard deviation on either side of mean values is represented by shaded area (moderate agonists) in the
graphs.
doi:10.1371/journal.pone.0017194.g001
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1mwa (PDB code), the MHC helices exhibit a ring of mostly
positive residues with one/two negative residues on either helix
contributing towards TR docking (Figure 2c). In such complexes,
the corresponding binding TR interface is almost completely
negatively charged, with one/two positive residues on either
variable domain (Figure 2d). Across the entire dataset, the positive
and negative arrangement seems to be by far more preferred than
a ring with predominantly a single charge. It was also observed
that negative charges on the two helices of both MHC-I and
MHC-II structures occur around the N-termini of bound peptides
whereas positive charges are located around their C-termini
(Figure 2a, c and e).
A vice versa arrangement of charges is seen on TR interacting
regions (Figure 2b, d and f). A noteworthy observation is that,
MSEP presented by almost all pMHC interfaces are overall
similar, suggesting that the ability of a TR to scan through many
pMHC interfaces is attributable to the common electrostatic rings
displayed on pMHC interfaces. Interestingly, a few, possibly key
positions on pMHC interfaces vary in the charges displayed across
the entire dataset. This is significant in the context of TR/pMHC
interaction because mutating specific charged interacting residues
on pMHC interfaces is known to cause increase or decrease in
experimentally determined TR/pMHC binding affinity due to
increased or decreased electrostatic interactions between the TR
and pMHC leading to an enhanced or reduced T cell response,
respectively [29]. As concluded in many earlier studies [16, 20, 28
and 33], our results confirm the importance of peptide in TR/
pMHC binding, opposing the notion that TR/pMHC interaction
is independent of peptide [4,34]. A proof of this is the fact that
various peptides display different combinations of positive and
negative residues (Figure 2c and e) which interact with
corresponding complementarily charged residues on highly
variable CDR3 loops of TR Va and Vb domains (Figure 2d
and f). Thus, the most variable regions of TR (CDR3) are
positioned in the center of binding interface where they contact
the peptide, whereas the more conserved regions of TR (CDR1
and CDR2) and the tops of MHC helices engage in contacts that
surround the central CDR3-peptide region like a ‘‘gasket’’ [4].
Therefore, MHC helices along with bound peptides, present a set
of electrostatic charges that are recognised by specific TR
domains.
However, these surfaces should also not be too highly charged
or they would bind other counter-ions that may need to be
removed and hence might compete with TR for interaction. To
support our theory, some short-(salt bridges) to long range (.4A ˚
Figure 2. An aerial view of the MSEP displayed by the pMHC interfaces of TR/pMHC-I complexes a. 2e7l (PDB code), c. 1mwa (PDB
code) and that of TR/pMHC-II complex e. 1u3h (PDB code) along with b, d, f. their respective contacting TR Va and Vb domain
interfaces rotated 1806 along their interacting axis to visualize their binding interface. The charged residues on the pMHC interfaces are
numbered, which interact with the corresponding complementary charges (numbered accordingly) on their respective TR Va and Vb domain
interfaces. These Va and Vb domain interfaces are collectively formed by the CDR1, CDR2 and CDR3 (shown as coloured dotted ovals in b.) loops that
interact with the pMHC. The locations of CDR1, 2 and 3 loops in b. are the same for the TR interacting regions in d. and f.
doi:10.1371/journal.pone.0017194.g002
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crystal structures. For example, between the D10 TR Va residue
Lys68 (IMGT unique numbering {referred to as IMGT} 82; [35])
and murine MHC-II (I-Ak) G-BETA residue Asp76 (IMGT 72) in
the PDB structure 1d9k [36] or between the A6 (PDB code 1ao7;
[3]), B7 (PDB code 1bd2; [37]) and 2C (PDB code 2ckb; [38]) TR
Va residue Lys68 (IMGT 82) and the murine/human MHC-I
(H2-Kb/HLA-A2) G-ALPHA2 residue Glu166 (IMGT 76) [6,39].
Amongst other examples, are the electrostatic interactions between
Glu52 (IMGT 63) residue of Vb CDR2 loop and Arg79 (IMGT
79) residue of HLA-B8 in TR/pMHC-I complex LC13/EBV/
HLA-B8 (PDB code 1mi5; [40]) and the interactions between the
human MHC-II (HLA-DR1 and HLA-DR4; PDB codes 1fyt and
1j8h, respectively) G-ALPHA residue Lys39 (IMGT 43) (in a loop
projecting up and away from the floor of b-sheet that forms the
base of MHC binding groove) and the Vb residue Glu56 (IMGT
67) of HA1.7 TR [16,41]. A recent molecular modeling study
proved that a single point mutation (G95R; IMGT 107) in Vb
CDR3 loop of 2C TR increased its affinity to QL9/Ld pMHC by
a factor of 1000. This, they suggest, is most likely due to direct
electrostatic interaction of Arg95 side chain with an Asp8 (IMGT
8) residue in the QL9 peptide nonamer [42]. Thus, electrostatic
effects can work at a distance [43], especially for orienting
purposes, so their role in orienting TR relative to pMHC at an
early stage during antigen recognition is vital.
It has been reported earlier that diagonal angle of TR docking
on pMHC varies between 22u–71u spanning a range of about 50u
[17]. Charges displayed on MHC helices, when considered
together, seem to present themselves at an angle. Utilizing the
location of these charges, we have computed the corresponding
TR docking angle (h) on each pMHC interface (see Methods
section for details). Our TR docking angle calculation results show
that apart from the PDB structure 1ymm (h of 112u; Table S1),
whose diagonal TR docking angle (110u) has been reported to
be of an unusually high value [44], h varies between 20u–87u over
the entire dataset (Figure 3), clearly overlapping the previously
reported range of 22u–71u [17] and extending it in both directions.
These results provide further evidence for docking of TR onto
pMHC interface at an angle such that the TR appears almost
‘‘diagonally’’ [17] attached to the pMHC surface. h for TR/
pMHC-II structures was generally around 72u while for TR/
pMHC-I complexes it was 42u on average. We note that when a
TR docks onto pMHC interface with a low h, the area covered by
TR paratope on pMHC interface is greater due to the increased
number of possible contacts between TR and pMHC interfaces
(Figure 4a), therefore, implying that smaller the h, stronger the
binding interaction between TR and pMHC and vice versa
(Figure 4b). This could possibly be one of the underlying reasons
as to why a recent TR-like antibody designing study has yielded a
Fab 3M4E5-based ‘‘Fab T1’’ antibody which gives a 20-fold
affinity improvement compared to Fab 3M4E5 (PDB code 3hae;
[45]) itself and exceeds the affinity of the original TR (1G4; PDB
code 2bnr; [26]) by 1,000-fold, thereby, resulting in increased T
cell cytotoxic activity [45]. The Fab 3M4E5 antibody (which itself
has a 100-fold improvement in affinity compared to the original
1G4 TR [45]) binds the peptide/HLA-A*0201 complex (PDB
code 3hae) at an angle of 40u [45] when compared to the diagonal
TR docking angle of 69u (h by our calculations is 39u) for the
original 1G4 TR (PDB code 2bnr) [26,45] and it makes more
contacts with the pMHC compared to the 1G4 TR causing
increased T cell cytotoxicity [45]. These additional interactions are
between the A*0201 G-ALPHA2 residue A158 (IMGT 69) and
the Fab 3M4E5 VH domain residues G56 & T58 (IMGT 63 and
65), A*0201 G-ALPHA2 residue Y159 (IMGT 70) and Fab
3M4E5 VH domain residue S57 (IMGT 64), A*0201 G-ALPHA2
domain residue T163 (IMGT 73) and Fab 3M4E5 VH domain
residues G55 & S57 (IMGT 62 and 64), A*0201 G-ALPHA2
domain residues E166 & W177 (IMGT 76 and 77) and Fab
3M4E5 VH domain residue S54 (IMGT 59), which cause a
change in the angle with which the antibody binds the pMHC
complex [45], thereby supporting our hypothesis.
BE is inversely proportional to h
Utilizing TR BE values computed for pMHC-I and pMHC-II
weak-, moderate- and strong agonists and h calculated using
MSEP on their pMHC binding interfaces, we have established a
significant correlation between BE and h, as shown in Figure 5.
Evidently, weak-agonists have a higher h when compared to
moderate-agonists and strong-agonists. Strong-agonists have the
least h amongst both TR/pMHC-I and TR/pMHC-II structures.
This observation clearly highlights the significance of the derived
correlation suggesting that for a given pMHC complex, TR BE is
inversely proportional to h and implying that, lower the h stronger
the binding between pMHC ligand and the respective TR and vice
versa. Graphs in Figure 5 are explanatory of the above said
correlation. Pearson correlation coefficient (r) between BE and h
for TR/pMHC-I complexes is 0.92 with a regression coefficient
(r
2) of 0.841. Similarly, for TR/pMHC-II complexes, Pearson
correlation coefficient (r) is 0.91 and regression coefficient
r
2=0.821. Interestingly, one TR/pMHC-I structure (1lp9; cyan
in Figure 5a) seems to be an outlier from our correlation despite
being classified as a strong-agonist. This was primarily owing to
the collaborative contribution of the Va CDR1, 2 and 3 loops
which bind strongly to the MHC G-ALPHA2 residues 154–167
(IMGT 65–77) and MHC G-ALPHA1 residues 65–69 (IMGT 65–
69) [46]. Comparatively, the binding exhibited by Vb CDR1
which only binds to the peptide residue F6 (IMGT 6) and Vb
CDR2 loops that bind to MHC G-ALPHA1 residues 65–72
(IMGT 65–72), respectively, is weak with only Vb CDR3 loops
binding strongly to MHC G-ALPHA2 residues 146–155 (IMGT
58–66), resulting in an overall greater diagonal TR docking angle
[46]. Therefore, the strong binding of Va CDR1, 2, 3 and Vb
CDR3 loops with MHC G-ALPHA1 and G-ALPHA2 residues
coupled with the tilt in the TR paratope due lack of interactions
between Vb CDR1 and MHC residues and weak interactions
Figure 3. TR docking angle (h) range computed using charge
distribution on pMHC interfaces with reference to the axis of
cognate peptide. Charges displayed on pMHC interface are located at
an angle (h) with respect to the axes of linear peptides (green), ranging
from 20u (yellow ellipse) to 87u (white ellipse) (spanning 68u) over the
entire dataset, which is similar to and overlaps the range of diagonal
angles (50u;2 2 u–71u) for TR docking reported earlier [17].
doi:10.1371/journal.pone.0017194.g003
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observations of the 1lp9 structure having an overall high TR/
pMHC BE and a relatively higher h value compared to other
strong-agonists. Hence, this outlier was removed from our
depicted correlation for TR/pMHC-I structures in Figure 5a.
Upon inclusion of the outlier, the Pearson correlation coefficient (r)
Figure 4. Relationship between h and area covered by TR paratope on pMHC interface. a. Small h value leading to a large interaction area
compared to b. Large h, resulting in a smaller paratope area. pMHC binding interface is shown as Ca trace with MHC helices in red and cognate
peptide in green. Ellipses represent TR paratopes on pMHC, which are at distinct small and large h with respect to the axis of bound peptides (angle
calculation is shown previously in Figure 3). Shaded regions within the ellipses denote corresponding areas covered by TR paratopes. These areas
clearly suggest large and small number of contacts that TR could make with pMHC in a. and b., respectively.
doi:10.1371/journal.pone.0017194.g004
Figure 5. Correlation between BE and h for a. pMHC-I agonists and b. pMHC-II complexes. The regression coefficients r
2=0.841 for pMHC-
I agonists and r
2=0.821 for pMHC-II complexes are shown. The single outlier (PDB code 1lp9) in a. is highlighted in cyan.
doi:10.1371/journal.pone.0017194.g005
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with a reduced regression coefficient (r
2) of 0.808.
TR paratope and pMHC epitope analyses reveal
conserved positions
Residues on TR variable domains that contact the residues on
pMHC interface are collectively referred to as ‘‘TR paratope’’.
Similarly, residues on pMHC interface that contact the residues on
TR variable domains are collectively termed as ‘‘pMHC epitope’’.
Analyzing TR paratope and pMHC epitope across a wide dataset
such as this is an important aspect in our quest to uncover the
physicochemical basis of TR specificity and pMHC selectivity.
Our results reaffirm the results of Garcia et al., [4] and Rudolf
et al., [15] that there were no major conserved contacts observed
between TR variable domains and pMHC interfaces over the
entire dataset. However, we note that there are sets of pMHC
ligands which have strikingly similar, even identical, patterns of
interacting residues. Same is the case with TR variable domains
which seem to fall into sets which show highly conserved patterns
of interacting residues. These sets, along with MSEP based cluster
dendograms (Fig. S1) and heat maps (Fig. S2) for pMHC interfaces
obtained from our MSEP analysis, were used to cluster TR
proteins (see Methods section for details). This characteristic was
prominent in both TR/pMHC-I and TR/pMHC-II sequences.
One, very significant and highly conserved contact was
observed on all 11 pMHC-II interfaces. This residue was Gln
(Q) 57 (IMGT 65), while Gly (G) 58 (IMGT 66) was mostly
conserved on MHC G-ALPHA helix (labeled in Figure 6c). These
residues are of utmost importance, as it could be this pair along
with a few peptide residues that the TR variable domains could be
looking for TR/pMHC complex formation in TR/pMHC-II
structures. Amongst TR/pMHC-II complexes, these residues,
perhaps serve as an alarm for TR signaling. Besides these
conserved residues, we identified several conserved positions on
the peptides, G-ALPHA1 and G-ALPHA2 MHC-I helices
(Figure 6a), G-ALPHA and G-BETA MHC-II helices (Figure 6c),
CDR1, CDR2 and CDR3 loops of respective pMHC-I and
pMHC-II binding TR Va and Vb domains (Figure 6 b and d).
These conserved residues and positions identified are listed in
Table 1.
At this stage there are no absolutely conserved residues found in
the interacting regions of TR/pMHC-I structures on the whole,
but, as said above, there seems to be grouping and a definite
pattern of conserved positions on interacting regions of both
pMHC and TR, which present different combination of residues
according to complementary MSEP displayed on corresponding
interacting regions. Therefore, specificity of TR for one pMHC
could possibly come from the specific pattern of interacting
residues exhibited by that particular pMHC ligand at the above
described conserved positions for both pMHC-I and pMHC-II.
Based on our observations, we suggest that conserved residues
along with residue variations at conserved positions form the basis
of TR selectivity and specificity. Hence, these results, together with
the common electrostatic rings seen on pMHC interfaces, explain
the ability of a TR to survey many pMHC complexes before
actually binding to one specific pMHC. Interestingly, number of
conserved positions for TR/pMHC-I structures, are less compared
to that of TR/pMHC-II structures. One fact that could be
attributed to such a result is the small proportion of TR/pMHC-II
structures (11) when compared to TR/pMHC-I (50) structures in
the current data. Nevertheless, one could easily comprehend that
with the increase in number of TR/pMHC-II structures, the
number of conserved positions would eventually decrease.
Combining the results from our TR paratope, pMHC epitope
and TR docking angle analyses, it is obvious that when a TR
docks onto a pMHC binding interface with an overall small h, the
number of contacts between pMHC and TR are greater, thereby,
increasing the area covered on pMHC interface by TR Va and
Vb domains (TR paratope; Figure 4a), compared to the area
covered when the TR docks with an overall large h (Figure 4b),
hence proving our earlier inference. This increase or decrease in
number of contacts between pMHC and TR according to the
decrease and increase in h, respectively, has a direct consequence
on BE between pMHC and TR as shown in the above correlation.
TR grouping is allele and species dependent but TR
specificity is peptide dependent
Calculation of MSEP similarities for all pMHC interfaces using
webPIPSA server [47] and CLUSTALX [48] multiple sequence
alignment of all TR paratopes and pMHC epitopes, have together
provided us substantial evidence to define grouping (clustering)
among TRproteins (see Methods sectionfor details).These analyses
formed the basis of our understanding of TR/pMHC binding and
pMHC recognition similarities shown by TR proteins. webPIPSA
uses the software R [49] for statistical computing and analytical
grouping to produce a dendrogram (Fig. S1) and generate a heat
map (Fig. S2). Table S1 portrays a clear clustering amongst TR
proteins obtained by summarizing the results of webPIPSA analysis
and multiple sequence alignment for TR paratopes and pMHC
epitopes. By initial mapping of respective MHC alleles onto cluster
dendograms in Figure S1, it was evident that similarities in MSEP
displayed by pMHC interfaces were allele based.
Further investigation by mapping corresponding TR types
(names for all TR proteins obtained from the literature) onto
cluster dendograms alongside MHC alleles revealed that many TR
proteins bind to same MHC allele which in turn is bound to
different peptides (Table S1). This implies that TR specificity is
perhaps primarily peptide dependent rather than completely allele
dependent, shedding light on the impact of peptide properties in
this significant immunological synapse, thus, further enforcing our
earlier conclusion and weakening the ‘‘TR-MHC germline bias’’
theory. As seen, there were three clusters identified among
pMHC-I binding TR proteins. Cluster I.1 comprises of six
different types of TR proteins all of which are known to bind
pMHC with murine MHC alleles. Cluster I.2 is made up of eight
TR types which behave in a more diverse fashion by binding to
pMHC with human alleles other than A*0201. Eight types of TR
proteins which recognize pMHC-I with A*0201 allele fall under
Cluster I.3. pMHC-II binding TR proteins were segregated into
two distinct clusters, where, Cluster II.1 has five types of TR
proteins which are associated with murine I-Au, I-Ag7 and I-Ak
alleles and Cluster II.2 includes four TR types associated with
human DR-alleles. These results are also noted to be species
specific since all murine pMHC structures are clustered together
implying that all TR types associated with murine MHC alleles are
clustered together. This adds another dimension to this significant
TR grouping system. It is worth noting that at the TR level the
MHC supertype definitions do not apply.
Interestingly, there are multiple PDB structures for a single TR/
pMHC complex, showing different TR binding angles, where we
have tested the validity of our inverse relationship between calculated
BE and h. 2f54 and 2bnr (PDB code; bold in Table S1) form one such
pair. Here, h for 2f54 was computed to be 36u which is 3u smaller
than that of 2bnr (39u). The calculated BE values for the two
structures are 215.6 kcal/mol (2f54) and 214.9 kcal/mol (2bnr),
respectively, which are inversely related to the h values. These subtle
changes in h and BE are due to the underlying fact that the side chain
Understanding TR Binding to pMHC Complexes
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hydrogen bond with the side chain of TR Va residue S51 (IMGT 58)
in 2f54 [50] resulting in a well ordered Q155 (IMGT 66) side chain,
when compared to its relatively disordered side chain orientation due
to hydrogen bond formation with the side chain of TR Va residue
T95 (IMGT 109) in 2bnr [26]. Similarly, 2vlj, 2vlk and 1oga (bold
and italics in Table S1) represent the same TR/pMHC complex,
with different TR docking orientations. Compared to that of 1oga
(69u; [17]), the diagonal TR docking angles for 2vlj and 2vlk are
reported to be roughly up to 5u larger [51], whereas our computed h
values are 1u and 1.5u larger than both the diagonal TR docking
angle and the computed h value for 1oga (69u), respectively. Their
respective calculated BE values are 211.7 kcal/mol (2vlj),
211.4 kcal/mol (2vlk) and 211.9 kcal/mol (1oga), which are in
accord with our computed h values and the diagonal TR docking
angles reported. Yet again, the core residues involved in TR/pMHC
interaction are conserved in all three of these structures and slight
variations in h and BE are a direct consequence of the subtle
positional changes accommodated by the peripheral residues at the
binding interface through regulations in their side chain conforma-
tions [51]. These are mainly MHC G-ALPHA1 residue Q72 (IMGT
72), MHC G-ALPHA2 domain residue Q155 (IMGT 66) and the
TR Vb residue I53 (IMGT 58) [51].
Discussion
We have analyzed available TR/pMHC structures using a
number of physicochemical characteristics to understand any basic
Figure 6. Residue conservation at pMHC and TR interfaces for a. pMHC-I ligands. b. pMHC-I binding TR. c. pMHC-II complexes and
d. pMHC-II-binding TR. Conserved residue Q57 (IMGT 65) and mostly conserved residue G58 (IMGT 66) on G-ALPHA helix of pMHC-II interface in c
are labelled. Conserved positions are labelled according to their chain locations on pMHC and TR interfaces. Highlighted in red are conserved
positions, a conserved residue and a mostly conserved residue on G-ALPHA1 helix of pMHC-I and G-ALPHA helix of pMHC-II interfaces in a. and c.,
respectively. Conserved positions on G-ALPHA2 helix of pMHC-I in a. are in gold. Residue positions on peptides are in blue and on G-BETA helix of
pMHC-II in c. are in orange. Conserved residues and positions in b. and d. are coloured according to their CDR loops as follows: Va CDR1: pink, CDR2:
cyan, CDR3: yellow, Vb CDR1: pale orange, CDR2: pale pink and CDR3: green. The colouring scheme used for CDR loops is the same used in Figure 2b.
Protein backbones are represented as Ca trace in grey.
doi:10.1371/journal.pone.0017194.g006
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The avidity of TR/pMHC interaction has been classified as weak-
, moderate-, and strong-, based on the BE values that were
computed for pMHC and TR binding interfaces. Using BE as a
discriminator between weak-, moderate- and strong-agonists will
add value to prediction methods enabling them to successfully
predict true T cell epitopes or strong-agonists that are highly likely
to initiate T cell response. Also, it would be interesting to
decompose BE into electrostatic and van der Waals components to
get an insight into the energetic contributions and correlate these
with the differing amino acids at the TR and pMHC interfaces.
We have also proposed a novel and rational approach to
computing h value by mapping charged rings formed from MSEP
on the pMHC interface. Here, we note from literature that,
although for some TR/pMHC crystal structures the entire TR
paratope is used to calculate the diagonal TR docking angle [17],
using the central mass of TR Va and Vb domains as a reference to
draw an axis [46,52] that cuts the cognate peptide axis at an angle
(generally much greater than the angle obtained by using the
entire paratope) appears to be the common practice of diagonal
TR docking angle calculation for most crystal structures. Hence,
the fact that we employ TR paratope, pMHC epitope and MSEP
at pMHC interfaces to procure the h values, could be the
fundamental reason for our h values being extremely close or fairly
distant to the diagonal TR docking angles reported for some
structures (Table S1). Results from our MSEP analysis explain the
common TR docking geometry on pMHC interface, seen in all
TR/pMHC structures. None of the structures available to us for
analysis has a glycan molecule at or near the TR/pMHC
interface. However, some of these molecules have a glycan shield
around them which may also contribute towards docking by
excluding certain modes of binding and helping in orientation of
TR [53]. This is a possible complexity that needs to be factored in
as more data becomes available. Using MSEP in epitope
prediction methods could further accelerate the progress of
structure-based prediction techniques besides minimizing false
positives and true negatives from actual agonistic peptides in a
given set of peptide antigens. We have reported a strong
correlation between BE values and h across the entire dataset
which solves the first query addressed in this manuscript (described
earlier in Introduction section). Analysis of TR paratopes and
pMHC epitopes revealed that although there are no absolutely
conserved residues found in interacting regions of both TR and
pMHC ligands, there are vital conserved positions on both
interfaces across TR/pMHC-I and TR/pMHC-II structures that
could have fundamental implication for peptide vaccine design.
Identification of conserved residues/positions on pMHC and TR
interacting regions provides clues to the positional specificity of
TR proteins. Furthermore, we have clustered TR proteins based
on their binding site similarities, pMHC recognition similarities
and similarities in MSEP on their respective interacting pMHC
interfaces, to dissect TR/pMHC binding requirements. MSEP
similarity calculation at the pMHC interface together with TR
paratope and pMHC epitope analyses have thus given us enough
evidence to suggest a weakening of ‘‘germline bias’’ theory over a
larger dataset and highlight the significant role played by the
peptide in determining TR specificity, thereby, answering our
second question (see Introduction section for details).
Based on our findings, we wish to propose a mechanism for
TR/pMHC binding and TR activation which explains the
phenomenon of pMHC recognition by TR and TR specificity
simultaneously. We suggest that, after peptide binding to MHC,
many similar pMHC complexes are presented on the cell surface
which exhibit similar charged rings of MSEP (explained earlier in
the results of our TR and pMHC interface MSEP analysis)
thereby signalling or attracting the TR towards them through
long-range electrostatic steering. Due to their electrostatic
similarity, the TR actually surveys many pMHC complexes. This
is possible by temporary interactions between the rings of charged
residues displayed on MHC helices and on CDR1 and CDR2
Table 1. List of conserved residues and positions.
MHC Class Structural Location Loop Conserved Residues Conserved Positions
I MHC G-ALPHA1 helix - - a65, a69 and a72
MHC G-ALPHA2 helix - - a150, a151 and a155
Peptide - - P4, P6, P7 and P8
TR Va CDR1 - a30
CDR2 - -
CDR3 - a99 and a100
TR Vb CDR1 - b30
CDR2 - -
CDR3 - b97 and b98
II MHC G-ALPHA helix - Q57 and G58 (mostly conserved) a61, a64 and a65
MHC G-BETA helix - - b67, b70, b73, b76, b77 and b81
Peptide - - P2, P4, P6, P8 and P9
TR Va CDR1 - a27, a29
CDR2 - a50
CDR3 - -
TR Vb CDR1 - b30 and b31
CDR2 - b48, b50 and b56
CDR3 - b96, b97 and b98
doi:10.1371/journal.pone.0017194.t001
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by the recognition of specific arrangements of pMHC residues (at
conserved positions) by CDR3 loops. Once this recognition occurs,
the TR localizes itself on the pMHC such that the half-life of TR/
pMHC complex is sufficiently stabilized for T cell activation.
Therefore, the entire process of pMHC recognition and TR
signalling is possibly governed by two factors, the electrostatic ring
displayed by pMHC interface and a specific arrangement of
residues presented by pMHC.
From our extensive studies on TR/pMHC interactions we have
defined structural features that can be analyzed as parameters
governing TR/pMHC complex formation relevant for immune
system activation. These parameters are MSEP of TR and pMHC
interfaces and TR docking angle (h), which, when coupled with the
knowledge of specific arrangement of residues at conserved
positions on TR and pMHC interfaces, could be used as
discriminants for in silico identification of strong-agonistic pMHC
complexes. Results of these analyses could be used to develop and/
or enhance methods to successfully predict T cell epitopes in
accordance with their MHC and TR binding specificities. This
could greatly improve the efficacy of T cell epitope prediction
models in separating true T cell epitopes from a large number of
predicted MHC-binding peptides. This kind of structure-based
screening helps overcome the barriers of insufficient training data
and lack of peptide binding motifs, especially for MHC-II alleles,
thereby cutting down the lead time involved in experimental
vaccine development methods, resulting in production of effective
and highly specific peptide vaccines with a wide population
coverage. Our results will facilitate the rational development of
peptide vaccines, capable of eliciting T cell response, for
immunotherapies to protect against or combat infectious,
autoimmune, allergic and graft vs. host diseases.
Methods
Data
The data used in this study comprises of 61 non-redundant TR/
pMHC structures from the MPID-T2 database (http://biolinfo.org/
mpid-t2) [8], which were originally obtained from the Protein Data
Bank (PDB) [9] and verified with the IMGT/3Dstructure-DB
(http://www.imgt.org/3Dstructure-DB/) database [10,11]. The
PDB structure 2icw was not included in this study as it has a
superantigen between the TR and the pMHC which prevents actual
TR/pMHC interaction by mediating the TR/pMHC binding [54].
Out of the 61 structures, 50 were MHC-I complexes spanning 9
alleles from human (7) and mouse (2) and 11 MHC-II complexes
spanning 7 alleles, again from human (4) and mouse (3). When there
is more than one structure with the same peptide sequence, MHC
allele and TR type, mutations in the MHC a (I-ALPHA) chain
(MHC-I), TR Va and Vb CDR2 & 3 loops and the degree of tilt or
relative change (compared to the first structure with similar TR type,
MHC allele and peptide sequence in Table S1) in h were taken into
account as primary criteria to consider the structures non-redundant.
Coordinates for truncated versions of the X-ray structures,
encompassing single structural complexes of the pMHC binding
interfaces and the variable domains of the TR were extracted for TR
paratope, pMHC epitope analyses and MSEP calculations.
BE calculation
The interaction of most ligands with their binding sites can be
characterized in terms of binding free energy or binding energy
(BE). In general, high energy TR/pMHC binding results from
greater intermolecular force between the pMHC and its TR while
low energy ligand binding involves less intermolecular force
between the pMHC and its TR. High energy binding involves a
longer residence time for the TR on its respective pMHC than in
the case of low energy binding. High energy binding of pMHC to
a TR is often physiologically important as some of the BE can be
used to cause a conformational change in the TR, resulting in a
physiological response or T cell response [55,56]. Since BE is also
referred to as binding free energy, the most negative value is
considered the best. In literature, BE (DG) is usually derived from
the binding constants of the interaction such as Kd and Ka.
The general thermodynamic formulae used are as follows:
DG~RTlnKd ð1Þ
Kd~1=Ka ð2Þ
where Kd is the dissociation constant, R is the universal gas
constant, T is the absolute temperature and Ka is the association
constant. BE values between the pMHC and TR for all TR/
pMHC structures were calculated using the program DCOM-
PLEX [57], which uses DFIRE-based potentials [58]. The
program first calculates the total atom-atom potential of mean
force, G, for each structure, which is given by:
G~
1
2
X
i,j
u i,j,ri,j
  
ð3Þ
where u ¯ is the atom-atom potential of mean force between two
atoms, i and j that are a distance r apart, the summation is over
atomic pairs that are not in the same residue and a factor of K is
used to avoid double-counting of residue-residue and atom-atom
interactions [57].
The binding free energy between two interacting proteins A and
B can also be obtained by using:
DGbind~Gcomplex{ GAzGB ðÞ ð 4Þ
where A and B are considered as two rigid bodies whose interface
residues contribute most to DGbind [57]. Therefore, the final
equation used by DCOMPLEX [57] to calculate BE is as follows:
DGbind~
1
2
S
interface
i,j
u i,j,ri,j
  
ð5Þ
DCOMPLEX provides an overall BE, without details of specific
components for electrostatic, van der Waals, hydrophobic and
entropic terms.
MSEP similarity calculation
MSEP in proteins is a result of charged side chains of the amino
acid residues and bound ions. These potentials play a vital role in
protein folding, stability, enzymecatalysis and specificprotein-protein
recognitions. MSEPsimilarity between any two protein molecules is a
measure of the similarity in their composition of charged residues.
Interactions between the TR and pMHC in all the structures depend
vastly on the charges that the binding site on the pMHC displays.
Thus,thewebserverwebPIPSA[47]wasusedtocalculatetheMSEP
and compare the electrostatic interaction properties of only the
pMHC binding interfaces in all the structures. The algorithm begins
with calculation of the protein MSEP and then calculates similarity
indices for all pairs of proteins based on the electrostatic similarity.
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which are then displayed as a colour coded matrix called as the heat
map (Fig. S2) and as a tree or a cluster dendogram (Fig. S1). These
cluster dendograms and heat maps were consequently used for TR
clustering (described below). Structural models of only the pMHC
interfaces were used for this analysis. ICM [59,60] was then used to
visually analyse the electrostatic images of all the structures.
Calculation of TR docking angles (h)
Similarly, we generated and visualized electrostatic images of the
TRbindinginterfaces(Vaand Vbdomains).TherespectivepMHC
and TR interfaces were then matched for complementarities of
charges and the corresponding charges were numbered accordingly
on both the interfaces (Figure 2). These charged residues were cross
verified with the list of pMHC and TR interacting residues collated
for TR paratope and pMHC epitope residue conservation analyses.
The charged residues missing from these lists were omitted and the
charges were renumbered for consistency in results. A line was
drawn which connects the numbers on each of the pMHC
interfaces using ICM [59,60]. Once connected, the numbers on a
given pMHC interface formed an ellipsoidal shape, which
determines the TR paratope on the pMHC (Figure 3). These
ellipses were noticed to be at a certain angle with respect to the Ca
backbone axes of the respective cognate peptides across the entire
dataset. Finally, straight lines were drawn diagonally across the
ellipses which cut the axes of the bound peptides at a given angle
(Figure 3). These angles were measured using ICM [59,60] and are
called TR docking angle (h) on the pMHC interfaces (Figure 3).
TR paratope and pMHC epitope residue conservation
analyses
These analyses required us to manually extrapolate and list the
interacting residues of the pMHC and TR for each structure either
from the literature or by using ICM [59,60] computer program.
CLUSTALX [48] was later used to perform multiple sequence
alignment in the hope of identifying any conserved patterns in the
interacting residues of pMHC and TR interfaces.
TR grouping
Initially, the sets of pMHC and TR interfaces, obtained from our
TR paratope and pMHC epitope residue conservation analyses,
showing similar pattern of interacting residues (mentioned earlier in
the Results section), were matched against the cluster dendograms
(Fig.S1) and heat maps (Fig.S2),to verifyif the structures that display
the sets observed in residue conservation analyses, are present within
distinct clusters of pMHC complexes (Fig. S1 and S2). After this
confirmation, the respective MHC alleles and corresponding TR
types were mapped onto the cluster dendograms which clearly
indicated the grouping (clustering) amongst the TR molecules based
on similarities in their binding site, pMHC recognition properties and
MSEP displayed on their respective interacting pMHC interfaces.
Supporting Information
Table S1 Grouping of TR proteins. Mutations in MHC a
(I-ALPHA) chain and TR Vb domain (MHC-I; TR Cluster I.2
and I.3), TR mutant names and the degree of tilt or relative
change (compared to the first structure with similar TR type,
MHC allele and peptide sequence) in h are mentioned in
parentheses (see Methods section for details).
(PDF)
Figure S1 Cluster dendograms for all pMHC interfaces
based on their MSEP similarities. a. pMHC-I complexes
clustered into three distinct clusters. b. pMHC-II ligands clustered
into two distinct clusters. Each pMHC interface is denoted by its
corresponding PDB code. Every pMHC is mapped onto its
respective MHC allele and the interacting TR type (TR name).
This clearly indicates the clustering amongst the TR proteins. The
three distinct clusters of pMHC-I binding TR proteins are coloured
yellow: cluster I.1, green: cluster I.2 and orange: cluster I.3. The two
clusters amongst pMHC-II binding TR proteins are highlighted in
light blue: cluster II.1 and lavender: cluster II.2. TR grouping
(clustering) is in accordance with Table S1.
(PDF)
Figure S2 Heat maps for all pMHC interfaces based on
the calculated MSEP values depicted as a colour coded
matrix showing clustering amongst pMHC complexes in
a reverse order as compared to the cluster dendograms
in Figure S1. a. pMHC-I complexes clustered into three. b.
pMHC-II structures in two distinct clusters. Each pMHC
interface is again denoted by its corresponding PDB code. Inset,
are the legends showing the color key used to create heat matrices
and the MSEP value ranges for pMHC interfaces. Also shown is
the formula used to calculate electrostatic distances for clustering.
(PDF)
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